AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 51 min read$NMTC

NeuroOne Medical Technologies Corporation (NMTC) Q4 Rev $3.8M, Up 38%; Wins $4.5M Order

NeuroOne reported preliminary Q4 FY26 revenue of $3.8M, up 38.4% YoY, and FY26 revenue of $10.5M. The company secured a $4.5M purchase order, with $1.0M shipped in September and $3.6M expected in Q1–Q2 FY27. Open purchase orders totaled $5.4M as of September 30.

Original reporting
tradingview.com
Published Oct 5, 2026, 1:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
NeuroOne Medical Technologies Corporation (NMTC) Q4 Rev $3.8M, Up 38%; Wins $4.5M Order — source image
Source · tradingview.com
Decision brief

The 30-second read

$NMTCBullishMed
01

Why it matters

The disclosed numbers represent the first public earnings data for the period, offering fresh insight into the company's growth trajectory.

02

Market read

First‑time earnings release for a microcap; may trigger modest price movement.

03

What to watch

Potential risk if backlog conversion slows or if the company faces cash‑flow constraints despite order growth.

Relevance 6/10Novelty 7/10Timing: post‑release today

Background

NeuroOne Medical Technologies released its preliminary Q4 FY26 results, highlighting a 38% YoY revenue increase and a $4.5M purchase order.

Company-level read

Ticker impact

$NMTCBullishMedium confidence
Context

Q4 FY26 product revenue $3.8M, up 38.4% YoY, and a new $4.5M purchase order disclosed.

Expected impact

modest upside as investors price in higher revenue and order visibility

Evidence & confidence

Small‑cap earnings beats typically generate short‑term buying pressure, especially with a fresh order pipeline.

Market effects

Sector

May lift sentiment for niche medical‑device microcaps showing revenue growth.

Regional

Limited to U.S. OTC/ Nasdaq microcap segment.

Global

Low; impact confined to company and similar small‑cap peers.

Counterpoint

What could challenge this read

Given the tiny absolute revenue, the beat may be priced in quickly and could lead to short‑term profit taking.

Key entities

  • company
    NeuroOne Medical Technologies Corporation

    US‑listed medical‑device firm reporting Q4 FY26 results.

Read at source← All news

Related articles

OCT 5
$NMTCLow

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

SEC EDGAR 8-K1 min
AUG 27
$NMTCMed

EQS-News: NeuroOne Medical Technologies: NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED Platform

NeuroOne Medical Technologies (NMTC) reported successful large-animal procedures using its StereoCED platform for drug delivery and electrophysiological monitoring. The company expects to launch human clinical studies this quarter and recognize related revenue in fiscal Q4 2026. The procedures were conducted at the University of Minnesota, demonstrating technical feasibility and validating the integrated surgical and drug delivery workflow.

finanznachrichten.de2 min
AUG 15
Med

NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary

NeuroOne Medical Technologies reported Q3 2026 revenue up 16%, driven by demand for its OneRF Brain Ablation System, though recognized revenue was limited by manufacturing lead times. Gross margin rose to 59.9%. Management cited ISO 13485 certification, guidance of $9.2M to $10.5M for FY2026, and a second manufacturing site expected in early 2027.

yahoo.com6 min
AUG 13
$NMTCMed

EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NeuroOne Medical Technologies (Nasdaq: NMTC) reported fiscal Q3 2026 results for the quarter ended June 30, 2026. Product revenue rose 16% YoY to $2.0M and product gross margins expanded to 59.9%. New product orders were $2.7M, lifting backlog to $1.7M, and FY2026 orders totaled $11.2M. The company also cited ISO 13485 certification and updates on StereoCED and OneRF platforms.

finanznachrichten.de7 min
AUG 13
$NMTCMed

NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne® Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9% $2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Wo

SEC EDGAR 8-K6 min
OCT 22
$ASBHighAI 8/10

Associated Banc-Corp Q3 2026 slides: margin hits decade high

Associated Banc-Corp (ASB) reported Q3 2026 earnings, beating estimates with adjusted EPS of $0.81. Net interest margin expanded to 3.20%, a decade high. Loans and deposits grew, with strategic shifts toward higher-yielding commercial relationships. Shares rose 2.16% to $29.81. Management maintained guidance for continued margin expansion.

investing.com3 min